依达拉奉治疗急性脑梗死患者的临床疗效及其对血清SOD、MDA水平的影响

郑慧芬, 宗惠花, 俞燕, 赵彦平

郑慧芬, 宗惠花, 俞燕, 赵彦平. 依达拉奉治疗急性脑梗死患者的临床疗效及其对血清SOD、MDA水平的影响[J]. 实用临床医药杂志, 2014, (17): 18-21. DOI: 10.7619/jcmp.201417006
引用本文: 郑慧芬, 宗惠花, 俞燕, 赵彦平. 依达拉奉治疗急性脑梗死患者的临床疗效及其对血清SOD、MDA水平的影响[J]. 实用临床医药杂志, 2014, (17): 18-21. DOI: 10.7619/jcmp.201417006
ZHENG Huifen, ZONG Huihua, YU Yan, ZHAO Yanping. Clinical effect of edaravone on treatment of patients with acute cerebral infarction and its influence on serum SOD and MDA[J]. Journal of Clinical Medicine in Practice, 2014, (17): 18-21. DOI: 10.7619/jcmp.201417006
Citation: ZHENG Huifen, ZONG Huihua, YU Yan, ZHAO Yanping. Clinical effect of edaravone on treatment of patients with acute cerebral infarction and its influence on serum SOD and MDA[J]. Journal of Clinical Medicine in Practice, 2014, (17): 18-21. DOI: 10.7619/jcmp.201417006

依达拉奉治疗急性脑梗死患者的临床疗效及其对血清SOD、MDA水平的影响

基金项目: 中国高校医学期刊临床专项资金
详细信息
  • 中图分类号: R743

Clinical effect of edaravone on treatment of patients with acute cerebral infarction and its influence on serum SOD and MDA

  • 摘要: 目的:观察依达拉奉治疗急性脑梗死患者的临床疗效及对血清超氧化物歧化酶(SOD)、丙二醛(MDA)的影响。方法选取64例急性脑梗死患者,随机分为治疗组33例,对照组31例。对照组给予基础药物治疗,治疗组在对照组的基础上给予依达拉奉,观察2组临床疗效、神经功能缺损改善总有效率及美国国立卫生研究院卒中量表(NIHSS)评分、日常生活能力Barthel指数量表评分,及血清SOD、MDA水平变化。结果治疗14 d后,治疗组总有效率为84.85%,对照组总有效率为61.29%,治疗组总有效率显著高于对照组(P<0.05)。治疗后2组患者的NIHSS、Barthel评分显著优于治疗前(P<0.01),组间比较有显著差异(P<0.05)。治疗后,治疗组的SOD水平显著高于治疗前(P<0.01),对照组患者的SOD水平显著低于治疗前(P<0.01),治疗组的MDA水平显著低于治疗前(P<0.01),对照组的MDA水平显著高于治疗前(P<0.05)。2组患者均无严重不良反应。结论在基础药物治疗上加用依达拉奉治疗急性脑梗死疗效确切安全。
    Abstract: Obj ective To observe the clinical effect of edaravone on treatment of patients with acute cerebral infarction (ACI)and its influence on serum superoxide dismutase (SOD)and malondialdehyde (MDA).Methods A total of 64 ACI patients were randomly divided into control group (31 cases)treated with basic medicines and treatment group (33 cases)added with with edar-avone.Clinical efficacy,neurological function deficit improvement rate,American National Insti-tutes of Health Stroke Scale (NIHSS)and Barthel index (BI)as well as serum SOD and MDA level changes in both groups were observed.Results 14 d after treatment,the clinical efficacy in treat-ment group was 84.85%,significantly higher than the 61.29% in control group (P<0.01). NIHSS and Barthel scores were better after treatment than those before (P<0.01),and differences between two groups were also significant (P<0 .05 ).After treatment,SOD level was higher in treatment group (P<0 .0 1 )and lower in control group than those before treatment (P<0 .0 1 ), whereas MDA level was lower in treatment group (P<0 .0 1 )and higher in control group than those before treatment (P<0 .05 ).Additionally,there had no severe adverse responses in both groups. Conclusion On the basis of basic treatment,the application of edaravone has favorable clinical effi-cacy and safety in the treatment of ACI .
  • 张千, 汪莉. 自由基清除剂依达拉奉在缺血性脑卒中的临床应用 [J]. 内科, 2009(4):617.doi: 10.3969/j.issn.1673-7768.2009.04.065.
    彭晓琴, 张兆辉, 何国厚. 依达拉奉联合银杏达莫治疗急性脑梗死的Meta分析 [J]. 卒中与神经疾病, 2012(3):159.doi: 10.3969/j.issn.1007-0478.2012.03.009.
    Nakase T, Yoshioka S, Suzuki A. Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in hu-man brain ischemic stroke [J]. BMC neurology, 20 1(1):39.
    陈敏, 陈艳红, 潘庆敏. 急诊期行高压氧治疗对脑梗死患者的临床疗效观察 [J]. 神经损伤与功能重建, 2012(3):198.doi: 10.3870/sjsscj.2012.03.012.
    祝春华, 张祥建. 脑出血后病理生理机制及临床治疗对策 [J]. 中国神经免疫学和神经病学杂志, 2012(3):47.doi: 10.3969/j.issn.1006-2963.2012.03.005.
    杨政, 吴玉林. 治疗急性脑梗死的新型脑保护药依达拉奉 [J]. 中国新药杂志, 2002, (12):911.doi: 10.3321/j.issn:1003-3734.2002.12.004.
    Kimura K, Aoki J, Sakamoto Y. Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients-A preliminary study [J]. Journal of the Neurological Sciences, 2012(1):132.
    Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction.Randomized, placebo-control ed, double-blind study at multicenters [J]. Cerebrovascular Diseases, 2003(3):222.
    印卫兵, 王蔚, 丁新生. 在中国应用依达拉奉治疗急性脑梗死临床疗效的Meta分析 [J]. 中国脑血管病杂志, 2009, (10):532.doi: 10.3969/j.issn.1672-6921.2009.10.008.
    韩秋果. 依达拉奉治疗急性脑梗死临床疗效及对SOD, MDA, CAT的影响 [D]. 长春:吉林大学, 2009.
    Aoki M, Warita H, Mizuno H. Feasibility study for functional test battery of SOD transgenic rat (H46R)and e-valuation of edaravone, a free radical scavenger [J]. Brain re-search, 2011.321.
    Hori K, Tsuji M, Iino T. Protective effect of edar-avone for tourniquet-induced ischemia-reperfusion injury on skeletal muscle in murine hindlimb [J]. BMC muscu-loskeletal disorders, 2013(1):113.
    魏林节, 冯国君, 童红让. 丹参注射液与依达拉奉联合治疗急性脑梗死的临床疗效观察 [J]. 临床神经病学杂志, 2014, (27):58.
    刘家斌, 李广生, 邓江华. 依达拉奉对急性反射性损伤兔组织核转录因子-kB表达和丙二醛含量的影响 [J]. 临床神经病学杂志, 2013, (26):358.
    张晓庆. 依达拉奉药理作用和临床应用的研究进展 [J]. 医药导报, 2011(7):918.doi: 10.3870/yydb.2011.07.029.
计量
  • 文章访问数:  225
  • HTML全文浏览量:  48
  • PDF下载量:  0
  • 被引次数: 0
出版历程
  • 发布日期:  2014-10-16

目录

    /

    返回文章
    返回